CDK9 as modifier of the IGF pathway and methods of use

Details for Australian Patent Application No. 2005265195 (hide)

Owner Exelixis, Inc.

Inventors Ollmann, Michael, Martin; Bjerke, Lynn, Margaret; Maxwell, Mark, E.; Heuer, Timothy, S.

Agent Davies Collison Cave

Pub. Number AU-A-2005265195

PCT Pub. Number WO2006/009933

Priority 60/581,689 21.06.04 US

Filing date 20 June 2005

Wipo publication date 26 January 2006

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

14 December 2006 PCT application entered the National Phase

  PCT publication WO2006/009933 Priority application(s): WO2006/009933

29 November 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005265200-Genetically purified gellan gum

2005265190-GALNTs as modifiers of the IGFR pathway and methods of use